Cardiology (all articles)
Opinion Video | Questioning the reliability of nutrition science
23 May, 2023 | 13:02h | UTC
Consensus Statement | Management of arrhythmias during pregnancy
23 May, 2023 | 13:00h | UTC2023 HRS Expert Consensus Statement on the Management of Arrhythmias During Pregnancy – Heart Rhythm
News Release: Management of Arrhythmias During Pregnancy Consensus Statement Emphasizes Shared Decision-Making – European Heart Rhythm
Consensus Statement | Practical management of the remote device clinic
23 May, 2023 | 12:58h | UTC
Guideline | Cardiac physiologic pacing for the avoidance and mitigation of heart failure
23 May, 2023 | 12:55h | UTCNews Release: New clinical practice guideline on cardiac physiological pacing – Elsevier
Review | Microcirculatory dysfunction in cardiogenic shock
23 May, 2023 | 12:50h | UTCMicrocirculatory dysfunction in cardiogenic shock – Annals of Intensive Care
Global variations in heart failure etiology, management, and outcomes
22 May, 2023 | 13:50h | UTCGlobal Variations in Heart Failure Etiology, Management, and Outcomes – JAMA (free for a limited period)
Author Interview: Global Trends in Heart Failure Etiology, Management, and Outcomes
News Release: Heart failure deadly and under-treated in most countries, says a study in 40 countries – McMaster University
Commentary on Twitter
Study of patients with heart failure (HF) from 40 different countries and from 4 different economic levels demonstrated differences in HF etiologies, management, and outcomes. https://t.co/uYH9jI8Q5Z
— JAMA (@JAMA_current) May 16, 2023
RCT | Remote pulmonary artery monitoring may improve QoL, reduce hospitalizations in symptomatic (NYHA III) heart failure
22 May, 2023 | 13:47h | UTCRemote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial – The Lancet (link to abstract – $ for full-text)
News Release: Remote monitoring reduces heart failure hospitalisations and improves quality of life – European Society of Cardiology
Commentary: CardioMEMS Beats Standard Care in First European RCT: MONITOR-HF – TCTMD
Commentary on Twitter
Remote monitoring reduces #HeartFailure hospitalisations and improves quality of life 👇#HeartFailure2023 #HF #HFA_ESC #MONIT0R_HF pic.twitter.com/Rvg1y45tCQ
— European Society of Cardiology (@escardio) May 20, 2023
RCT | Apixaban fails to match warfarin in preventing valve thrombosis in On-X mechanical heart valve patients
22 May, 2023 | 13:44h | UTCApixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve – NEJM Evidence
Commentary: Apixaban or Warfarin in Patients With On-X Mechanical Aortic Valve – American College of Cardiology
Commentary on Twitter
“…in patients with an On-X mechanical aortic valve, apixaban was not noninferior to warfarin and failed to meet our safety threshold… for the prevention of valve thrombosis or valve-related thromboembolism.” https://t.co/XEcOJiGIYU#CardioTwitter #Afib
— NEJM Evidence (@NEJMEvidence) May 11, 2023
AHA Statement | Addressing diabetes and atherosclerosis in Asian American adults: insights, management, future steps
22 May, 2023 | 13:42h | UTCNews Release: Culture, diet, economic factors and more affect CVD risk among Asian Americans – American Heart Association
Commentary: Think Differently: Diabetes, CVD Risks in Asian Americans Not Uniform, AHA Says – TCTMD
Commentary on Twitter
Examining Asian American subgroups separately is crucial to understanding different mechanisms that contribute to T2D & ASCVD risks. The new scientific statement: https://t.co/taTVvXtXd2 @CircAHA @kwancardio @SallySWong @alka_kanaya @HeartDocSadiya @SvatiShah @FFR81 @hayman_ll pic.twitter.com/lWtl1AKBKg
— AHA Science (@AHAScience) May 8, 2023
Underdiagnosis of primary aldosteronism: a review of screening and detection
22 May, 2023 | 13:40h | UTC
Commentary on Twitter
Underdiagnosis of Primary Aldosteronism: A Review of Screening and Detection https://t.co/PYzSCZD2L7 (FREE)@MarioFunesMD @BhallaResearch @StanfordNeph pic.twitter.com/k7intLqpK3
— AJKD (@AJKDonline) May 19, 2023
SCAI Consensus Statement | Management of in-stent restenosis and stent thrombosis
22 May, 2023 | 13:41h | UTCNews Release: Guidance on management of in-stent restenosis and stent thrombosis – Society for Cardiovascular Angiography and Interventions
New pharmacological agents and novel cardiovascular pharmacotherapy strategies
22 May, 2023 | 13:24h | UTC
Commentary on Twitter
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022: a focused review by the ESC Working Group on #Pharmacotherapy 💊 https://t.co/DZ6FTqYwxk @jpkaski #HF #AFib #diabetes #lipids #EHJPharmacotherapy @AgewallStefan @FeliceGragnano pic.twitter.com/1DTCewbyPv
— European Society of Cardiology Journals (@ESC_Journals) May 20, 2023
Review | Sarcopenia and cardiovascular diseases
22 May, 2023 | 13:22h | UTCSarcopenia and Cardiovascular Diseases – Circulation
Stent angioplasty in coronary artery anomalies with intramural course: when, why, how, with what results?
16 May, 2023 | 14:38h | UTC
Commentary on Twitter
Comprehensive review on #PCI for #CoronaryArteryAnomalies. CAA are associated w cardiac death in select patients w ectopic origins. Acute ischemia may be seen in young athletes & #PCI may be appropriate in select patients.
➡️ https://t.co/j4ELX7jZxp @SarasVallabhMD @RizikMd pic.twitter.com/fHSXeIftcU
— MyJSCAI (@MyJSCAI) May 2, 2023
RCT | Rivaroxaban doesn’t reduce thrombotic events, hospitalization, or death in outpatients with COVID-19
15 May, 2023 | 13:19h | UTCSummary: The PREVENT-HD trial, a double-blind, placebo-controlled randomized study, was conducted to evaluate the effectiveness of prophylactic anticoagulation in reducing venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor. The trial took place between August 2020 and April 2022 across 14 US integrated healthcare delivery networks, with 1,284 patients enrolled and randomly assigned to receive either 10 mg of oral rivaroxaban or placebo daily for 35 days.
However, the study was terminated prematurely due to enrollment challenges and lower-than-expected event rates. The primary efficacy outcome, a composite of various hazardous events, occurred in 3.4% of the rivaroxaban group and 3.0% of the placebo group, with no significant difference between the two groups (hazard ratio, 1.16 [95% CI, 0.63–2.15]; P=0.63). No critical-site or fatal bleeding was observed, and only one patient in the rivaroxaban group experienced a major bleed.
In conclusion, rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis does not appear to reduce the composite end point of venous and arterial thrombotic events, hospitalization, and death. The study’s premature termination and lower-than-expected event rates may limit the generalizability of these findings.
Commentary on Twitter
#OriginalArticle: In this #RCT, Rivaroxaban did not appear to reduce a composite endpoint of venous and arterial thrombotic events, hospitalization, and death among non‐hospitalized patients with symptomatic COVID‐19 #AHAJournals https://t.co/PhdXnTJ0V9 pic.twitter.com/f04uYu2M5f
— Circulation (@CircAHA) May 10, 2023
RCT | Statins do not prevent early cardiac dysfunction in anthracycline-treated cancer patients
15 May, 2023 | 13:07h | UTCStatins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines – European Heart Journal – Cardiovascular Pharmacotherapy (link to abstract – $ for full-text)
Commentary on Twitter
Primary prevention with atorvastatin during anthracycline therapy did not prevent cardiac dysfunction and myocardial tissue changes: SPARE-HF randomized trial https://t.co/9s2p9JSSq4 #echofirst #HF #LVEF #CMR #ESCYoung #EHJPharmacotherapy @FeliceGragnano @AgewallStefan pic.twitter.com/7tKG4tdpcD
— European Society of Cardiology Journals (@ESC_Journals) May 13, 2023
Review | Heart failure and liver disease: cardiohepatic interactions
15 May, 2023 | 13:06h | UTCHeart Failure and Liver Disease: Cardiohepatic Interactions – JACC: Heart Failure
Cohort Study | Outcomes of surgery in cardiac angiosarcoma
12 May, 2023 | 13:35h | UTC
Commentary on Twitter
A study in #JACCCardioOnc from US national cancer database identifies 239 patients w/ rare cardiac tumor angiosarcoma:
🔸 Surgery is underutilized
🔸 Higher income, recentness of Dx, early stage, use of surgery, & #chemotherapy had a better outcome— JACC Journals (@JACCJournals) May 6, 2023
Review | Progress in the treatment of acute pulmonary embolism and chronic thrombo-embolic pulmonary hypertension/disease
12 May, 2023 | 13:24h | UTCSee all articles in the series here
Review | Treatment of amyloidosis: present and future
12 May, 2023 | 13:22h | UTCTreatment of amyloidosis: present and future – European Heart Journal Supplements
See all articles in the series here
Review | Takotsubo syndrome: more frequent in women, more dangerous in men
12 May, 2023 | 13:21h | UTCSee all articles in the series here
Review | Dilemmas in cardiology: when to recanalize a chronic total occlusion
12 May, 2023 | 13:19h | UTCSee all articles in the series here
Cohort Study | Adverse outcomes and rehospitalization more common for young women after acute myocardial infarction
11 May, 2023 | 12:18h | UTCSex Difference in Outcomes of Acute Myocardial Infarction in Young Patients – Journal of the American College of Cardiology (link to abstract – $ for full-text)
News Releases:
Commentaries:
Rehospitalizations After Acute MI: Young Women Outpace Young Men – TCTMD
Commentary on Twitter
Young women with #AMI face higher risk for repeat hospitalization after discharge compared to men. https://t.co/QC9NjCflnU#JACC #cvAMI #VIRGO #WomensHealth @MitsuakiSawano @hmkyale pic.twitter.com/iHorGCDoDF
— JACC Journals (@JACCJournals) May 6, 2023
Blood pressure variability in clinical practice: past, present and the future
11 May, 2023 | 12:13h | UTC
Aspirin for primary prevention of cardiovascular disease: what do the current USPSTF guidelines say?
11 May, 2023 | 12:11h | UTCOriginal Guideline: USPSTF Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease.
Related Randomized Trials:
Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease
Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes
Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
Related Meta-Analysis:
Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events
Related Opinions:
Aspirin for Primary Prevention: Is This the End of the Road?
Evidence evolving on aspirin as prevention – ACP Internist
#347 USPSTF Update: Aspirin for Primary Prevention of CVD – The Curbsiders